Taysha Gene Therapies, Inc. Stock Price, News & Analysis

Taysha Gene Therapies (NASDAQ:TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, will host its Q2 2025 financial results conference call on August 12, 2025, at 8:30 AM ET. The company will present its financial performance for the quarter ended June 30, 2025, along with a corporate update.

Investors can access the call via toll-free number (877-407-0792) or international line (201-689-8263) using conference ID 13754869. A webcast will also be available on the company's investor relations website.

Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee. The inducement grant includes options to purchase 90,000 shares at an exercise price of $2.63 per share under the company's 2023 Inducement Plan.

The stock option has a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.

Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted stock options to two new employees. The Compensation Committee approved options to purchase 30,000 shares of common stock at an exercise price of $2.34 per share under the company's 2023 Inducement Plan.

The options have a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has granted stock options to two new employees. The Compensation Committee approved options to purchase 401,000 shares of common stock under the company's 2023 Inducement Plan on June 2, 2025. The options have an exercise price of $2.785, matching the closing price on the grant date, with a 10-year term. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.

Taysha Gene Therapies (NASDAQ: TSHA) announced three oral presentations and a symposium at the 2025 IRSF Rett Syndrome Scientific Meeting in Boston from June 9-11, 2025. The presentations will cover clinical data from TSHA-102 trials, including high and low dose cohorts from REVEAL adolescent/adult and pediatric Phase 1/2 trials, caregiver research on developmental milestones, and preclinical data on AAV9 vector biodistribution. The company will also host a symposium on Rett syndrome natural history data findings. Dr. Sukumar Nagendran, President and Head of R&D, emphasized TSHA-102's potential to improve function and quality of life for Rett syndrome patients. The presentations align with FDA discussions on potential registration pathways and demonstrate the company's progress in developing gene therapy treatments for this severe CNS disorder.

Taysha Gene Therapies (NASDAQ: TSHA) has announced the pricing of a public offering, consisting of 46,868,687 shares of common stock at $2.75 per share and pre-funded warrants to purchase 25,858,586 shares at $2.749 per warrant. The company expects to raise approximately $200.0 million in gross proceeds before deducting expenses.

The underwriters have a 30-day option to purchase up to an additional 10,909,090 shares. The offering, led by joint book-running managers Jefferies, BofA Securities, Piper Sandler, and Barclays, is expected to close around May 30, 2025. Taysha is a clinical-stage biotechnology company developing AAV-based gene therapies for severe CNS monogenic diseases.

Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has announced a new public offering of common stock and pre-funded warrants. The offering includes an option for underwriters to purchase up to an additional 15% of shares within 30 days. Jefferies, BofA Securities, Piper Sandler, and Barclays are serving as joint book-running managers for the offering.

The offering will be conducted under a shelf registration statement that was filed with the SEC on December 13, 2024, and became effective on December 20, 2024. The final size, terms, and completion of the offering will depend on market conditions.

Taysha Gene Therapies (NASDAQ: TSHA) has announced pivotal trial design details for TSHA-102 in Rett syndrome, supported by FDA alignment and positive clinical data. The trial design is based on natural history data showing patients ≥6 years have a ~0% chance of gaining developmental milestones. Key highlights include:

The pivotal Part B trial will be a single-arm, open-label study (N=15) in patients ≥6 years old. Remarkably, Part A results showed 100% of patients (N=10) gained/regained ≥1 developmental milestone post-treatment, with the high dose showing superior results compared to low dose.

The treatment has been well-tolerated with no treatment-related serious adverse events. The company plans to submit the pivotal trial protocol this quarter and initiate the trial in Q3 2025. The trial's primary endpoint will assess developmental milestone gain/regain, with patients serving as their own control.

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 2025 financial results and provided updates on its TSHA-102 program for Rett syndrome. The company received FDA alignment on pivotal Part B trial design, allowing direct submission of the trial protocol as an IND amendment in Q2 2025, potentially expediting study initiation. Safety data shows both high dose (1x1015 vg) and low dose (5.7x1014 vg) of TSHA-102 are well-tolerated with no treatment-related SAEs or DLTs in 10 patients across REVEAL trials. Financially, Q1 2025 showed R&D expenses of $15.6M (down from $20.7M in Q1 2024), net loss of $21.5M ($0.08 per share), and cash position of $116.6M, expected to fund operations into Q4 2026. The company will present three oral presentations at the upcoming IRSF Rett Syndrome Scientific Meeting in June 2025.